All In Biotech

Drug Trial Radar · NCT00392925

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Effect on Body Weight of Recombinant-Methionyl Human Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Last checked: Nov 20, 2026Latest source record: Apr 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

177

Actual

Start

Oct 2006

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 26, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.

Conditions

  • Overweight
  • Obesity

Interventions

  • pramlintide acetate 360 mcgDrug

    subcutaneous injection, twice a day, 360mcg

  • metreleptinDrug

    subcutaneous injection, twice a day, 5mg

  • placebo-pramlintide 600 uLDrug

    twice a day

  • placebo-metreleptin 1 mLDrug

    twice a day

  • Pramlintide acetate 180 mcgDrug

    subcutaneous injection twice a day, 180 mcg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable PopulationTime frame: Baseline to Week 16

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    DeLand, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Overland Park, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Detroit, Michigan

  • Research Site

    Edina, Minnesota

  • Research Site

    Butte, Montana

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Olympia, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.